Clinical TopicsMedicationsNews
Migraine

New treatment for migraine

Author(s): By Lydia L. Kim, Digital Content Editor
Share

The U.S. Food and Drug Administration (FDA) recently approved Allergan’s ubrogepant (Ubrelvy) for treatment of acute migraine with or without visual disruptions (aura).

The FDA’s acting director of the Office of Neuroscience describes the impact of the approval: “Migraine is an often disabling condition that affects an estimated 37 million people in the U.S…Ubrelvy represents an important new option for the acute treatment of migraine in adults, as it is the first drug in its class approved for this indication. The FDA is pleased to approve a novel treatment for patients suffering from migraine and will continue to work with stakeholders to promote the development of new safe and effective migraine therapies.”

Please read more about ubrogepant’s here.

Source:
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine

Get your free subscription to the Women's Healthcare Newsletter!

Women's Healthcare Newsletter Sidebar

Enter your email to receive our bi-weekly newsletter from the publishers of Women's Healthcare

  • This field is for validation purposes and should be left unchanged.
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Quiz

According to the CDC, approximately how many women will develop breast cancer in their life?
You must be logged in to post a comment.

Poll

Get your free subscription to the Women's Healthcare Newsletter!

Women's Healthcare Newsletter Sidebar

Enter your email to receive our bi-weekly newsletter from the publishers of Women's Healthcare

  • This field is for validation purposes and should be left unchanged.
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.